Periorbital Richter Syndrome

Figure 1. Richter syndrome affecting eyelids on the left side in our patient.

In a patient with CLL and cutaneous necrosis of the orbit, additional to the more common fungal and infective causes, although NF is less common, as an aggressive potentially deadly soft-tissue/fascial infection, it should be considered and either ruled out or treated.⁶ The necrosis associated with NF (Fig 2) is, on examination, difficult to distinguish from that of Richter syndrome (Fig 1). Clinically, suspicion of both NF and Richter syndrome would be raised by clinical deterioration, but NF is expected to have a more acute (hours as opposed to days) time frame. The blistering, necrosis, and potential cutaneous thrombosis observed would not tend to demarcate into the more stable pattern, as seen with Richter syndrome, where the area affected corresponds to the basin of cutaneous CLL as opposed to progressive soft-tissue/fascial infection. The distinguishing factors included the more indolent course of Richter syndrome, as compared with NF, a failure to respond to antifungal/viral/bacterial therapies, and the need for an early biopsy. Conversely, on the basis of reviews of periorbital NF, using the rate of necrotic progression, or whether lesions demarcate, may not be a wholly reliable way to distinguish it from Richter syndrome. Luksich et al⁷ somewhat controversially report that ocular NF presents less aggressively than in the rest of the body and may be treated conservatively. Given such presentations, the diagnostic suspicion of NF in this case is more understandable, but actually confounds the choice not to biopsy, prior to debridement. This error was made because of a lack of awareness of Richter syndrome and communication between the hematology and surgical specialties.

Figure 2. Necrotizing fasciitis affecting both eyes.

Not only is Richter syndrome frequently a difficult diagnosis to establish but it also presents a therapeutic challenge. Treatment of Richter syndrome is primarily through the administration of monoclonal antibodies, chemotherapy, and steroids in the acute care setting.⁸ Radiotherapy may be also be used in combination to control pain, lymphadenopathy, and neurological/spinal cord manifestations. Standard chemotherapies used in CLL are not effective, and most clinicians rely on combined CHOP-R therapy for diffuse large B-cell lymphoma: cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab.⁸ With complete remission difficult to achieve, the use of allogeneic stem-cell transplantation has shown early promise but is still in its infancy. The choice of the plastic surgery team to debride down to orbicularis was likely to have only added insult to an already immunocompromised patient, where prompt institution of steroids, targeted monoclonal antibodies, and chemotherapy would have given the patient the best outcome.